Molecular detection of hrHPV-induced high-grade squamous intraepithelial lesions of the cervix through a targeted RNA next generation sequencing assay.

Journal: Molecular medicine (Cambridge, Mass.)
Published Date:

Abstract

BACKGROUND: Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high-risk human papillomaviruses (hrHPV), the causative agents of cervix cancer. Although hrHPV infection is a pre-requisite for the development of most precancerous lesions, the mere detection of viral nucleic acids, also present in transient infections, is not specific of the underlying cellular state, resulting in poor positive predictive values (PPV) regarding lesional states. There is a need to increase the specificity of molecular tests for better stratifying individuals at risk of cancer and to adapt follow-up strategies.

Authors

  • Julia Faillace Thiesen
    Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, 25-28 Rue du Dr. Roux, 75015, Paris, France.
  • Elise Jacquemet
    Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, 25-28 Rue du Dr. Roux, 75015, Paris, France.
  • Pascal Campagne
    Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, 25-28 Rue du Dr. Roux, 75015, Paris, France.
  • Denis Chatelain
    Centre Hospitalier Universitaire d'Amiens, Département de Pathologie, Amiens, France.
  • Etienne Brochot
    Amiens Picardie University Hospital, Research Department, Biobanque de Picardie (BRIF N BB-0033-00017), 80000, Amiens, France.
  • Yves-Edouard Herpe
    Amiens Picardie University Hospital, Research Department, Biobanque de Picardie (BRIF N BB-0033-00017), 80000, Amiens, France.
  • Nolwenn M Dheilly
    Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, 25-28 Rue du Dr. Roux, 75015, Paris, France.
  • Fabrice Bouilloux
    Biomnigene SA, 25000, Besançon, France.
  • Bénédicte Rognon
    Biomnigene SA, 25000, Besançon, France.
  • Alexandre Douablin
    Biomnigene SA, 25000, Besançon, France.
  • Guillaume Leboucher
    Labtoo, 17000, La Rochelle, France.
  • Florent Percher
    Labtoo, 17000, La Rochelle, France.
  • Marc Eloit
    Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, 25-28 Rue du Dr. Roux, 75015, Paris, France.
  • Philippe Pérot
    Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, 25-28 Rue du Dr. Roux, 75015, Paris, France. philippe.perot@pasteur.fr.